Morgan Stanley Frequency Therapeutics, Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$0.35 - $0.72 $10,844 - $22,308	30,984 Added 735.79%	35,195 $13,000
Q2 2023 Aug 14, 2023	SELL	$0.33 - $0.48 $27,194 - $39,555	-82,408 Reduced 95.14%	4,211 $1,000
Q1 2023 May 15, 2023	BUY	$0.44 - $5.47 $28,173 - $350,244	64,030 Added 283.46%	86,619 $43,000
Q4 2022 Feb 14, 2023	SELL	$1.88 - $3.85 $13,934 - $28,536	-7,412 Reduced 24.71%	22,589 $86,000
Q3 2022 Nov 14, 2022	SELL	$1.46 - $2.55 $52,378 - $91,483	-35,876 Reduced 54.46%	30,001 $54,000
Q2 2022 Oct 27, 2022	BUY	$1.03 - $2.03 $14,323 - $28,229	13,906 Added 26.76%	65,877 $99,000
Q2 2022 Aug 15, 2022	BUY	$1.03 - $2.03 $14,323 - $28,229	13,906 Added 26.76%	65,877 $99,000
Q1 2022 Oct 27, 2022	SELL	$1.7 - $5.72 $23,640 - $79,542	-13,906 Reduced 21.11%	51,971 $110,000
Q1 2022 May 13, 2022	SELL	$1.7 - $5.72 $252,291 - $848,888	-148,407 Reduced 74.06%	51,971 $110,000
Q4 2021 Feb 14, 2022	SELL	$4.95 - $7.11 $1.63 Million - $2.34 Million	-328,440 Reduced 62.11%	200,378 $1.03 Million
Q3 2021 Nov 15, 2021	BUY	$6.96 - $9.25 $3.68 Million - $4.89 Million	528,818 New	528,818 $3.73 Million

Ticker FREQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,262,000
Description
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candi...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.